Oncology Based In-vivo CRO Market Size Projected To Reach USD 1.5 Billion By 2025 : Grand View Research Inc.

Oncology Based In-vivo CRO Market Size Projected To Reach USD 1.5 Billion By 2025 : Grand View Research Inc.

“Grand View Research, Inc. – Market Research And Consulting”
According to report published by Grand View Research, owing to innovation in the field of genetic, efforts towards studying the oncogene and growing concern of pharmaceutical companies towards optimizing their research findings are certain vital impact rendering drivers of the Oncology Based In-vivo CRO market.

According to a report,” Oncology Based In-vivo CRO Market Analysis By Indication (Blood cancer, Solid tumor), By Model (Syngeneic model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2018 – 2025 ” published by Grand View Research, Inc., The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.

Key Takeaways from the report:

  • Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.
  • Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.
  • Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital based funding for CROs.
  • Few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
  • A common trend observed is the rising partnerships among CROs to offer bundle packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand their oncology based drug discovery service portfolio.

U.S. oncology based in-vivo CRO market, by indication, 2014 – 2025 (USD Million)

 

U.S. oncology based in-vivo CRO market, by indication, 2014 - 2025 (USD Million)

Browse More Reports in Pharmaceuticals Industry: 

Pruritus Therapeutics Market :Growing prevalence of conditions associated with pruritus such as atopic dermatitis, urticaria, and psoriasis is expected to serve the market as a high impact rendering drivers.

Anxiety Disorders And Depression Treatment Market :The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.

Global oncology based in-vivo CRO market, by model, 2016 (%)

Global oncology based in-vivo CRO market, by model, 2016 (%)

 

 Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.

Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.

Grand View Research has segmented the global oncology based in-vivo CRO market on the basis of indication, and region:

Global Oncology Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Blood cancer

  • Solid tumors

    • Syngeneic model

    • Patient Derived Xenograft (PDX)

    • Xenograft

  • Others

Oncology in-vivo CRO Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

For more information: www.grandviewresearch.com

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/oncology-based-in-vivo-cro-market